The market is getting excited over higher Relenza royalties and we are likely to see this released tomorrow night with higher demand from seasonal use and also from the UK and Japanese orders. However in my mind the really big development has been LANI and it's rapid progression through phase III. Given it's benefits as a once only treatment and one puff a week prophalactic it should be able to make giant leaps into the $6.5bn stockpiling market. A ROW marketing deal is also possible.
There has been some computer trading, a good sign.
BTA Price at posting:
81.0¢ Sentiment: Buy Disclosure: Held
